Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN

• Liquid biopsy monitoring is feasible in head and neck cancer patients. • Cell-free DNA mutations after surgery identify patients at risk for early relapse. • Increasing variant allele frequencies precede clinical progression.